101 related articles for article (PubMed ID: 25455655)
21. Successful pregnancy occurring with interferon-alpha therapy in chronic myeloid leukemia.
Mesquita MM; Pestana A; Mota A
Acta Obstet Gynecol Scand; 2005 Mar; 84(3):300-1. PubMed ID: 15715542
[No Abstract] [Full Text] [Related]
22. Expression of LYN and PTEN genes in chronic myeloid leukemia and their importance in therapeutic strategy.
Ferri C; Bianchini M; Bengió R; Larripa I
Blood Cells Mol Dis; 2014; 52(2-3):121-5. PubMed ID: 24091144
[TBL] [Abstract][Full Text] [Related]
23. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
Steinberg M
Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072
[TBL] [Abstract][Full Text] [Related]
24. Current opinions and controversies in chronic myeloid leukaemia.
Kishore B; Marin D
Curr Opin Oncol; 2011 Nov; 23(6):659-64. PubMed ID: 21918441
[TBL] [Abstract][Full Text] [Related]
25. BCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia: a review.
An X; Tiwari AK; Sun Y; Ding PR; Ashby CR; Chen ZS
Leuk Res; 2010 Oct; 34(10):1255-68. PubMed ID: 20537386
[TBL] [Abstract][Full Text] [Related]
26. Successful pregnancy involving a man with chronic myeloid leukemia on dasatinib.
Oweini H; Otrock ZK; Mahfouz RA; Bazarbachi A
Arch Gynecol Obstet; 2011 Jan; 283(1):133-4. PubMed ID: 20473616
[TBL] [Abstract][Full Text] [Related]
27. Ponatinib: A new tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.
Shamroe CL; Comeau JM
Ann Pharmacother; 2013 Nov; 47(11):1540-6. PubMed ID: 24265264
[TBL] [Abstract][Full Text] [Related]
28. Cost sharing and adherence to tyrosine kinase inhibitors for patients with chronic myeloid leukemia.
Dusetzina SB; Winn AN; Abel GA; Huskamp HA; Keating NL
J Clin Oncol; 2014 Feb; 32(4):306-11. PubMed ID: 24366936
[TBL] [Abstract][Full Text] [Related]
29. [ABL domain kinase point mutations as a cause of resistance to therapy of patients with chronic myeloid leukemia with tyrosine kinase inhibitors. Single center experience].
Sacha T; Foryciarz K; Florek I; Zawada M; Czekalska S; Cwynar D; Pecek E; Skotnicki AB
Przegl Lek; 2011; 68(5):253-7. PubMed ID: 21961412
[TBL] [Abstract][Full Text] [Related]
30. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial.
Mahon FX; Réa D; Guilhot J; Guilhot F; Huguet F; Nicolini F; Legros L; Charbonnier A; Guerci A; Varet B; Etienne G; Reiffers J; Rousselot P;
Lancet Oncol; 2010 Nov; 11(11):1029-35. PubMed ID: 20965785
[TBL] [Abstract][Full Text] [Related]
31. [Predictive value of molecular response after treatment with tyrosine kinase inhibitor for 3 months in patients with chronic myeloid leukemia].
Geng SX; Weng JY; Huang X; Lu ZS; Wu P; Huang LS; Liu L; Du X
Zhonghua Xue Ye Xue Za Zhi; 2013 Jul; 34(7):561-5. PubMed ID: 23906446
[TBL] [Abstract][Full Text] [Related]
32. Gab2 signaling in chronic myeloid leukemia cells confers resistance to multiple Bcr-Abl inhibitors.
Wöhrle FU; Halbach S; Aumann K; Schwemmers S; Braun S; Auberger P; Schramek D; Penninger JM; Laßmann S; Werner M; Waller CF; Pahl HL; Zeiser R; Daly RJ; Brummer T
Leukemia; 2013 Jan; 27(1):118-29. PubMed ID: 22858987
[TBL] [Abstract][Full Text] [Related]
33. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome.
Druker BJ; Sawyers CL; Kantarjian H; Resta DJ; Reese SF; Ford JM; Capdeville R; Talpaz M
N Engl J Med; 2001 Apr; 344(14):1038-42. PubMed ID: 11287973
[TBL] [Abstract][Full Text] [Related]
34. Liposomal cytarabine for treatment of myeloid central nervous system relapse in chronic myeloid leukaemia occurring during imatinib therapy.
Aichberger KJ; Herndlhofer S; Agis H; Sperr WR; Esterbauer H; Rabitsch W; Knöbl P; Haas OA; Thalhammer R; Schwarzinger I; Sillaber C; Jäger U; Valent P
Eur J Clin Invest; 2007 Oct; 37(10):808-13. PubMed ID: 17727673
[TBL] [Abstract][Full Text] [Related]
35. Interferon-alpha therapy for chronic myeloid leukemia during pregnancy.
Regierer AC; Schulz CO; Kuehnhardt D; Flath B; Possinger K
Am J Hematol; 2006 Feb; 81(2):149-50. PubMed ID: 16432865
[No Abstract] [Full Text] [Related]
36. Pregnancy in Patients With Chronic Myeloid Leukemia.
Berman E
J Natl Compr Canc Netw; 2018 May; 16(5S):660-662. PubMed ID: 29784750
[TBL] [Abstract][Full Text] [Related]
37. Impact of comorbidities on the treatment of chronic myeloid leukemia with tyrosine-kinase inhibitors.
Gugliotta G; Castagnetti F; Fogli M; Cavo M; Baccarani M; Rosti G
Expert Rev Hematol; 2013 Oct; 6(5):563-74. PubMed ID: 24083631
[TBL] [Abstract][Full Text] [Related]
38. Pregnancy under treatment of imatinib and successful labor in a patient with chronic myelogenous leukemia (CML). Outcome of discontinuation of imatinib therapy after achieving a molecular remission.
Ali R; Ozkalemkaş F; Ozçelik T; Ozkocaman V; Ozan U; Kimya Y; Köksal N; Gülten T; Yakut T; Tunali A
Leuk Res; 2005 Aug; 29(8):971-3. PubMed ID: 15978950
[TBL] [Abstract][Full Text] [Related]
39. Three novel patient-derived BCR/ABL mutants show different sensitivity to second and third generation tyrosine kinase inhibitors.
Redaelli S; Mologni L; Rostagno R; Piazza R; Magistroni V; Ceccon M; Viltadi M; Flynn D; Gambacorti-Passerini C
Am J Hematol; 2012 Nov; 87(11):E125-8. PubMed ID: 23044928
[TBL] [Abstract][Full Text] [Related]
40. Apoptosis in chronic myeloid leukemia cells transiently treated with imatinib or dasatinib is caused by residual BCR-ABL kinase inhibition.
Simara P; Stejskal S; Koutna I; Potesil D; Tesarova L; Potesilova M; Zdrahal Z; Mayer J
Am J Hematol; 2013 May; 88(5):385-93. PubMed ID: 23420553
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
